Skip to main content

Life Sciences is now live. See how →

Patent Examiner Sean E. Aeder

Art Unit 1642 · Antibodies, Cancer Immunotherapy & Diagnostics · Tech Center 1600 · 332 applications filed 2021–2026

⚑ Very Hard · harder than 84% of examiners● Free examiner data

Sean E. Aeder is a USPTO patent examiner in Art Unit 1642 (Antibodies, Cancer Immunotherapy & Diagnostics) with 332 applications from filing years 2021–2026. Examiner Aeder's allowance rate is 58.3%, below the 82.4% USPTO average for applications filed in the same years. The examiner ranks harder than 84% of examiners. In 2021, decided applications with an examiner interview were allowed 41.4 percentage points more often than those without.

Data through November 2026 from USPTO Patent Center (formerly PAIR) · Methodology

Overview

Free
Difficulty · Very Hard
harder than 84% of examiners
Easier84th percentileHarder
Allowance rate vs peers
Examiner Aeder58.3%
Art Unit 164254.4%
USPTO average82.4%
Allowance rate
58.3%
▼ USPTO avg 82.4%
Applications
332
filing years 2021–2026
First-action allowance
1.9%
patented with no rejection
Abandoned
25.9%
share of applications
Avg office actions
1.7
USPTO avg 1.4
Days to first OA
742
▲ USPTO 627
RCE rate
24.4%
USPTO 20.6%
Interview rate
16.3%
USPTO 28.3%

Examiner details

  • Art unit1642 · Antibodies, Cancer Immunotherapy & Diagnostics
  • Title / gradePrimary Patent Examiner · GS-14
  • Service22 years
  • PhoneOn each office action
  • Email[email protected]
  • In USPTO recordsAEDER, SEAN E
Full signatory authority

Examiner Aeder can allow an application without a supervisory sign-off.

Examines (USPC classes)
424 · Drug, Bio-Affecting & Body Treating Compositions435 · Chemistry: Molecular Biology & Microbiology530 · Chemistry: Natural Resins, Peptides or Proteins & Lignins

How to improve your odds with Examiner Aeder

  • The data favors an interview. Interviewed cases were allowed more often in all 3 measured years, by 22.8 to 41.4 points.
  • Plan for the timeline. First office action averages 742 days vs the 627-day USPTO norm.
  • Expect a §103. Obviousness is the most-issued rejection (179), and applicants overcame it 41.4% of the time.
  • The data favors an RCE here. Cases with an RCE were allowed more often in all 3 measured years, by 12.5 to 23.7 points.

Historical patterns from this examiner's past cases, shown for general information. This is not legal advice and does not predict the outcome of any specific application. Decisions about interviews, RCEs, and claim strategy should be made with a licensed patent attorney or agent.

Rejection patterns & how they get overcome

Free
§101 Eligibility72 issued · 51.6% overcome
§102 Novelty90 issued · 48.6% overcome
§103 Obviousness179 issued · 41.4% overcome
§112 Definiteness & disclosure172 issued · 59.9% overcome
How applicants traverse §103 rejections🔒 Members

Of the 26 winning responses to Examiner Aeder's §103 rejections that Boundly has classified, 20 (77%) amended the claims and argued, 4 argued without amending, and 2 amended without arguing. Each winning response, with its arguments and claim amendments, is in the file wrapper.

Read the winning §103 argumentsFull REMARKS, amendments, claim trees & redlines from the file wrappers
Start free

Just got an office action from Examiner Aeder?

Draft your response with Examiner Aeder's record and Art Unit 1642's history in view, including the rejection patterns, the interview record, and the arguments that have overcome them. See the office action response tools in AI Studio.

Open AI Studio free →

RCE behavior

Allowance after a Request for Continued Examination versus without one, per year. Use it to judge whether an RCE is worth the cost in front of Examiner Aeder.

YearRCE rateAllowance w/ RCEAllowance w/oDelta
202320.4%66.7%54.2%+12.5pp
202229.6%83.3%59.6%+23.7pp
202130.9%65.0%47.3%+17.7pp

Recent outcomes

Free🔒 Case detail for members
App #TitleOutcomeOAsArguments & redline
18/256556High-Affinity Mycobacterium Tuberculosis Capsule-Specific Human Monoclonal AntibodyPatented1🔒 View
17/908291New Method and Compound for Prostate Cancer DiagnosisPatented2🔒 View
19/384849IL-4R and TSLP Inhibitors and Methods of Use ThereofPatented1🔒 View
17/666999Methods for Identifying and Treating High-Plasticity Cell State Driving Tumor Progression in Lung CancerPatented7🔒 View
See all 332 applications with full file-wrapper detailOffice action text, attorney arguments, amendments & claim-by-claim track changes
Start free

Art Unit 1642 technology

Bispecific & engineered antibodiesAntibody conjugates & fusion proteinsImmune cell therapies & cancer vaccinesCancer diagnostics & biomarkersTop CPC A61K · C07K · G01N
About this examiner. Sean E. Aeder examines in Art Unit 1642 (Antibodies, Cancer Immunotherapy & Diagnostics, Tech Center 1600). Working on compound or antibody claims? See Life Sciences in AI Studio.

Frequently asked questions

What is Examiner Sean E. Aeder's allowance rate?
Examiner Aeder's allowance rate is 58.3%, compared with 82.4% across the USPTO and 54.4% in Art Unit 1642 for applications filed in the same years. That rate ranks Examiner Aeder harder than 84% of examiners.
Is Examiner Aeder a hard examiner?
Yes. Examiner Aeder ranks harder than 84% of examiners, in the 84th difficulty percentile (very hard). Examiner Aeder has a 58.3% allowance rate versus 82.4% across the USPTO and 54.4% in Art Unit 1642, 1.7 office actions per application versus 1.4, and an RCE rate of 24.4% versus 20.6% across the USPTO, for applications filed in the same years.
Do examiner interviews help with Examiner Aeder?
In this examiner's record, yes. Decided applications with an interview were allowed more often in each of the 3 measured years, by 22.8 to 41.4 percentage points. In 2021, 85.7% of decided applications with an interview were allowed, versus 44.3% of those without.
What is Examiner Aeder's most common rejection?
§103 obviousness, issued 179 times in the data. Applicants overcame it 41.4% of the time. Of the 26 winning responses Boundly has classified, 20 amended the claims and argued.
Is an RCE worth filing with Examiner Aeder?
In this examiner's record, yes. Decided applications with an RCE were allowed more often in each of the 3 measured years, by 12.5 to 23.7 percentage points. In 2021, 65.0% of decided applications with an RCE were allowed, versus 47.3% of those without one.
How long until the first office action from Examiner Aeder?
About 742 days on average, versus 627 days across the USPTO for applications filed in the same years.
How do I contact Examiner Sean E. Aeder?
Examiner Aeder can be reached by email at [email protected]. The examiner's direct line is listed at the end of the examiner's office actions.

Put Examiner Aeder's data to work on your next response.

Full file-wrapper detail, winning arguments, and AI-assisted drafting in one workspace.

Start free
Statistics are computed by Boundly Prosecution Intel from USPTO Patent Center (formerly PAIR) file wrappers for filing years 2021–2026, refreshed regularly. Allowance rate (sometimes called grant rate) is the share of disposed applications that issued as patents. Office actions here are non-final and final rejections, so restriction requirements and allowances are not counted. USPTO benchmarks are weighted to each examiner's mix of filing years, and art-unit benchmarks to the art units and filing years of the examiner's own applications, so they compare like for like. The difficulty percentile ranks examiners, each counted once, so it can point the other way from the USPTO average, which counts applications. See how each number is computed. The year-by-year interview and RCE tables show up to four recent filing years, leaving out the newest one and any year with fewer than ten applications or five decided applications on either side. Historical data is provided for informational purposes only. Past examiner behavior does not guarantee future outcomes, and nothing here is legal advice or a substitute for advice from a licensed patent attorney or agent. Are you Sean E. Aeder, or see an error? Request a correction.